ABPI warns that local reimbursement decisions may increase variation in drug uptake
This article was originally published in Scrip
New data show that the uptake of drugs in England approved by HTA institute, NICE, can vary dramatically from region to region. The data indicates that planned reforms of the UK's National Health Service that will further localise reimbursement could make the situation worse, warns the Association of the British Pharmaceutical Industry (ABPI).
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.